5 Key Takeaways

• 1

  Elinzanetant reduced moderate to severe vasomotor symptoms in postmenopausal patients at 12 weeks compared to placebo in a phase 3 trial.

• 2

  Patients taking elinzanetant experienced a mean reduction of 5.4 daily hot flashes, while those on placebo had a reduction of 3.5.

• 3

  The trial enrolled 628 postmenopausal patients aged 40 to 65 years across 83 sites in North America and Europe.

• 4

  Adverse events occurred in 70% of elinzanetant patients, with somnolence, fatigue, and headache being the most common.

• 5

  The study noted limitations, including underrepresentation of Asian and Pacific Islander patients and exclusion of those with recent cancer histories.